advertisement
Abstract #47060 Published in IGR 13-3
Efficacy and safety of latanoprost versus travoprost for primary open-angle glaucoma and ocular hypertension: A meta-analysis
Qian Z-G; Ke M; Huang G; Zou JChinese Journal of Evidence-Based Medicine 2011; 11: 965-970
Objective To evaluate the efficacy and safety of latanoprost versus travoprost for primary open-angle glaucoma (OAG) and ocular hypertension (OH). Methods. All the randomized controlled trials (RCTs) about treating primary open-angle glaucoma and ocular hypertension with latanoprost and travoprost were collected by searching MEDLINE, EMbase, OVID and CNKI. The assessment of methodological quality and data extraction of the included studies were performed independently by two reviewers, and the meta-analysis was conducted with RevMan 5.0 software. Results A total of 13 RCTs involving 1 433 patients were included. The results of meta-analyses showed that, a) At the second week, travoprost showed greater intraocular pressure (IOP) lowering efficacy compared with latanoprost (WMD= -1.47, 95%CI -2.62 to -0.33). At the first month (WMD= -0.50, 95%CI -1.52 to 0.52) and the sixth month (WMD= -0.12, 95%CI -0.85 to 0.61), the difference of IOP reduction between latanoprost and travoprost group was not significant; and b) the latanoprost-treated group showed fewer reported conjunctival congestion than the travoprost-treated group (OR=0.47, 95%CI 0.35 to 0.63). The difference in adverse events of eye pain (OR=0.55, 95%CI 0.27 to 1.12) and iris or skin depigmentation (OR=1.25, 95%CI 0.53 to 2.92) between latanoprost and travoprost group was not significant. Conclusion Latanoprost and travoprost are comparable in lowering IOP for OAG and OH patients. Latanoprost shows greater ocular tolerability with lower incidence of side effects as conjunctival congestion. This conclusion is not powerful enough in proof due to the medium methodology quality of the included studies, so a large number of high-quality RCTs with large sample are needed for objectively, entirely and precisely evaluating the efficacy.
Z.-G. Qian. Department of Ophthalmology, Xiangyang Center Hospital, Xiangyang 441021, China.
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)